Conference 2021 Poster Presentation

 

Project title

Immunoinformatics design of multiepitopes peptide-based universal cancer vaccine using matrix metalloproteinase-9 protein as a target

 

Authors and Affiliations

Abdelrahman H.Abdelmoneim1, Mujahed I. Mustafa2, Miyassa I. Abdelmageed3, Naseem S. Murshed4, Enas A. Dawoud5, Enas M. Ahmed6, Rahman M. Kamaleldin6, Nafisa M. Elfadol7, Anfal Osama M. Sati5, Abdelrafie M. Makhawi2

1. Faculty of Medicine, Alneelain University, Khartoum, Sudan
2. Department of Biotechnology, University of Bahri, Khartoum, Sudan
3.Faculty of Pharmacy, University of Khartoum, Khartoum, Sudan
4.Department of Microbiology, International University of Africa, Khartoum, Sudan
5.Faculty of Medical Laboratory Sciences, Razi University, Khartoum, Sudan
6. Faculty of Medicine, Karary University, Khartoum, Sudan
7. National University Biomedical Research Institute, National University, Khartoum, Sudan

 

Abstract

Background

Cancer remains a major public health hazard despite the extensive research on it over the years. A new approach toward cancer treatment is the use of cancer vaccine, yet the different molecular bases of cancers reduce the effectiveness of this approach. In this work, we aim to use matrix metalloproteinase-9 protein (MMP9) which is an essential molecule in the survival and metastasis of all type of cancers as a target for universal cancer vaccine design.

Methods

Reference sequence of matrix metalloproteinase-9 protein was obtained from NCBI databases along with the similar sequences, which is then checked for conservation using BioEdit software; furthermore, the B cell and T cell related peptides were analyzed using IEDB website and other related soft wares. The best candidate peptide were then visualized using chimera software

Results

Three Peptides found to be good candidate for interactions with B cells (SLPE, RLYT, and PALPR), while ten peptides found as a good targets for interactions with MHC1 and another 10 peptides founded suitable for interactions with MHC2 with population coverages of 94.77%. and 90.67% respectively. Finally, the immune response simulation and molecular docking was done using C-IMMSIM simulator and AutoDock Vina to confirm the effectiveness of the proposed vaccine.

Conclusions

Twenty-three peptide-based vaccine was designed for use as a universal cancer vaccine which has a high world population coverage for MHC1 (94.77%) and MHC2 (90.67%) related alleles.

 


Qries